Spotlight Therapeutics

Spotlight Therapeutics, founded in 2017 by Alex Marson, Jacob Corn, and Patrick Hsu, is a pioneering biotechnology company with a focus on creating biologics for specific cell populations through gene editing. With its innovative slogan, "Biotechnology company that develops biologics targeted to specific cell populations in gene editing," the company aims to revolutionize the landscape of direct in vivo gene editing.

Headquartered in the United States, Spotlight Therapeutics concentrates its therapeutic efforts predominantly in oncology, leveraging engineered nucleases to alter targeted disease organs at a genetic level. The team is rapidly expanding, particularly in areas such as protein engineering and immuno-oncology, to support rigorous preclinical development efforts.

The company garnered significant investor attention with its $36.50M Series B round on March 22, 2022, backed by a roster of esteemed investors, including GV, Emerson Collective, Magnetic Ventures, EPIQ Capital Group, GordonMD Global Investments, and Team Builder Ventures. This backing underscores the market potential of Spotlight's cutting-edge gene editing platform.